Across the recent three months, 8 analysts have shared their insights on Neurocrine Biosciences NBIX, expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 3 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Neurocrine Biosciences, revealing an average target of $151.88, a high estimate of $200.00, and a low estimate of $140.00. This upward trend is apparent, with the current average reflecting a 7.72% increase from the previous average price target of $141.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of how financial experts perceive Neurocrine Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jay Olson | Oppenheimer | Raises | Outperform | $200.00 | $170.00 |
| Anupam Rama | JP Morgan | Lowers | Overweight | $148.00 | $154.00 |
| David Hoang | Citigroup | Lowers | Neutral | $140.00 | $141.00 |
| Uy Ear | Mizuho | Raises | Neutral | $140.00 | $116.00 |
| Mohit Bansal | Wells Fargo | Raises | Equal-Weight | $140.00 | $127.00 |
| Chris Shibutani | Goldman Sachs | Raises | Buy | $153.00 | $134.00 |
| Carter Gould | Barclays | Raises | Overweight | $150.00 | $145.00 |
| Paul Matteis | Stifel | Raises | Buy | $144.00 | $141.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Neurocrine Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Neurocrine Biosciences compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Neurocrine Biosciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Capture valuable insights into Neurocrine Biosciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Neurocrine Biosciences analyst ratings.
All You Need to Know About Neurocrine Biosciences
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Financial Milestones: Neurocrine Biosciences's Journey
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Neurocrine Biosciences's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 25.05%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Neurocrine Biosciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 28.67%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Neurocrine Biosciences's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 6.98%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Neurocrine Biosciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 4.84%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.19, Neurocrine Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Significance of Analyst Ratings Explained
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
